Analyst Price Target is $14.43
▲ +214.35% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Annexon in the last 3 months. The average price target is $14.43, with a high forecast of $30.00 and a low forecast of $7.00. The average price target represents a 214.35% upside from the last price of $4.59.
Current Consensus is
Buy
The current consensus among 6 contributing investment analysts is to buy stock in Annexon. This Buy consensus rating has held steady for over two years.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Read More
